Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
29 studies found for:    " April 29, 2009":" May 29, 2009"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
Rank Status Study
21 Unknown  Trends in Risk Factors for Mother-to-Child Transmission of Hepatitis C Among a Southern European Population
Conditions: Hepatitis C Virus;   HIV Infections;   Pregnancy
Intervention:
22 Completed Vitamin D Supplementation and CD4 Count in HIV-Infected Children
Condition: HIV
Interventions: Dietary Supplement: Vitamin D;   Drug: No supplementation
23 Completed
Has Results
Safety and Efficacy of Cobicistat-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
Condition: HIV-1 Infection
Interventions: Drug: COBI;   Drug: RTV;   Drug: ATV;   Drug: FTC/TDF;   Drug: COBI placebo;   Drug: RTV placebo
24 Withdrawn Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women
Condition: HIV-1 Infections
Interventions: Drug: TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily;   Drug: TDF/FTC + Efavirenz (Atripla) Once-Daily
25 Completed Examining Hair to Determine Tenofovir Exposure
Condition: HIV
Intervention: Drug: Tenofovir Disoproxil Fumarate
26 Completed A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions
Conditions: Postherpetic Neuralgia;   Diabetic Neuropathy;   Complex Regional Pain Syndrome;   Carpal Tunnel Syndrome;   HIV Neuropathy;   Idiopathic Sensory Neuropathy;   Peripheral Neuropathy
Interventions: Drug: Placebo Capsules + Placebo Patch;   Drug: Placebo capsules + Lidoderm®;   Drug: Gabapentin + Placebo;   Drug: Gabapentin + Lidoderm®;   Drug: Gabapentin 300 mg capsules 1800 mg/day + placebo patch;   Drug: Gabapentin 1800 mg/day + Lidoderm patch
27 Completed A Study of Safety, Tolerability and Immunogenicity of a 1-Dose Regimen of MRKAd5 HIV-1 Gag Vaccine Versus the ALVAC_HIV Vaccine (V520-019)
Condition: HIV-1 Infection
Interventions: Biological: V520;   Biological: Comparator: ALVAC-HIV vaccine
28 Completed
Has Results
CyberSenga: Internet-based HIV Prevention in Uganda
Conditions: Sexual Abstinence;   Condom Use
Intervention: Behavioral: CyberSenga
29 Withdrawn Collecting and Storing Blood Samples From Patients With Cancer
Conditions: Brain and Central Nervous System Tumors;   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Nonmalignant Neoplasm;   Unspecified Adult Solid Tumor, Protocol Specific;   Unspecified Childhood Solid Tumor, Protocol Specific
Intervention:

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-29) Next Page   
Indicates status has not been verified in more than two years